Ultrasound enhanced antitumor activity of liposomal doxorubicin in mice

References

• Allen TM, Cleland LG. (1980). Serum-induced leakage of liposome contents. Biochim Biophys Acta, 597, 418–426.
   PubMed Web of Science ®Google Scholar
• Atchley AA, Frizzell LA, Apfel RE, Holland CK, Madanshetty S, Roy RA. (1988). Thresholds for cavitation produced in water by pulsed ultrasound. Ultrasonics, 26, 280–285.
   PubMed Web of Science ®Google Scholar
• Batist G. (2007). Cardiac safety of liposomal anthracyclines. Cardiovasc Toxicol, 7, 72–74.
   PubMed Web of Science ®Google Scholar
• Bonté F, Juliano RL. (1986). Interactions of liposomes with serum proteins. Chem Phys Lipids, 40, 359–372.
   PubMed Web of Science ®Google Scholar
• Charrois GJ, Allen TM. (2003). Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity. J Pharmacol Exp Ther, 306, 1058–1067.
   PubMed Web of Science ®Google Scholar
• Cohen J, Cohen P, West SG, Aiken LS. (2003). Applied multiple regression/correlation analysis for the behavioral sciences (3rd ed.) Mahwah, NJ: Erlbaum.
   Google Scholar
• Cui J, Li C, Guo W, Li Y, Wang C, Zhang L, Zhang L, Hao Y, Wang Y. (2007). Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy? J Control Release, 118, 204–215.
   PubMed Web of Science ®Google Scholar
• Davidsen J, Vermehren C, Frokjaer S, Mouritsen OG, Jørgensen K. (2001). Drug delivery by phospholipase A(2) degradable liposomes. Int J Pharm, 214, 67–69.
   PubMed Web of Science ®Google Scholar
• Deng CX, Xu Q, Apfel RE, Holland CK. (1996). In vitro measurements of inertial cavitation thresholds in human blood. Ultrasound Med Biol, 22, 939–948.
   PubMed Web of Science ®Google Scholar
• Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. (1999). Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev, 51, 691–743.
   PubMed Web of Science ®Google Scholar
• Dvorak J, Zoul Z, Melichar B, Petera J, Vesely P, Vosmik M, Dolezel M. (2004). Liposomal doxorubicin combined with regional hyperthermia: reducing systemic toxicity and improving locoregional efficacy in the treatment of solid tumors. J Chemother, 16 Suppl 5, 34–36.
   PubMedGoogle Scholar
• Evjen TJ, Nilssen EA, Rögnvaldsson S, Brandl M, Fossheim SL. (2010). Distearoylphosphatidylethanolamine-based liposomes for ultrasound-mediated drug delivery. Eur J Pharm Biopharm, 75, 327–333.
   PubMed Web of Science ®Google Scholar
• Ewer MS, Martin FJ, Henderson C, Shapiro CL, Benjamin RS, Gabizon AA. (2004). Cardiac safety of liposomal anthracyclines. Semin Oncol, 31, 161–181.
   PubMed Web of Science ®Google Scholar
• Favier J, Lapointe S, Maliba R, Sirois MG. (2007). HIF2 alpha reduces growth rate but promotes angiogenesis in a mouse model of neuroblastoma. BMC Cancer, 7, 139.
   PubMed Web of Science ®Google Scholar
• Frenkel V. (2008). Ultrasound mediated delivery of drugs and genes to solid tumors. Adv Drug Deliv Rev, 60, 1193–1208.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Goren D, Horowitz AT, Tzemach D, Lossos A, Siegal T. (1997). Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev, 24:337–44.
   Web of Science ®Google Scholar
• Gabizon A, Shiota R, Papahadjopoulos D. (1989). Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst, 81, 1484–1488.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Barenholz Y. (2003). Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet, 42, 419–436.
   PubMed Web of Science ®Google Scholar
• Huang SL, MacDonald RC. (2004). Acoustically active liposomes for drug encapsulation and ultrasound-triggered release. Biochim Biophys Acta, 1665, 134–141.
   PubMed Web of Science ®Google Scholar
• Jang SH, Wientjes MG, Lu D, Au JL. (2003). Drug delivery and transport to solid tumors. Pharm Res, 20, 1337–1350.
   PubMed Web of Science ®Google Scholar
• Lasic DD. (1993). Liposomes from Physics to Applications. Amsterdam: Elsevier Science Publishers B.V.
   Google Scholar
• Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release, 65, 271–284.
   PubMed Web of Science ®Google Scholar
• Myhr G, Moan J. (2006). Synergistic and tumour selective effects of chemotherapy and ultrasound treatment. Cancer Lett, 232, 206–213.
   PubMed Web of Science ®Google Scholar
• Needham D, Dewhirst MW. (2001). The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev, 53, 285–305.
   PubMed Web of Science ®Google Scholar
• Ogawa R, Kondo T, Honda H, Zhao QL, Fukuda S, Riesz P. (2002). Effects of dissolved gases and an echo contrast agent on ultrasound mediated in vitro gene transfection. Ultrason Sonochem, 9, 197–203.
   PubMed Web of Science ®Google Scholar
• Pearson ES, Hartley HOE. (1976). Biometrika Tables for Statisticians (vol 1). Biometrica Trust, University College London.
   Google Scholar
• Pitt WG, Husseini GA, Staples BJ. (2004). Ultrasonic drug delivery–a general review. Expert Opin Drug Deliv, 1, 37–56.
   PubMedGoogle Scholar
• Pretlow TG, Wolman SR, Micale MA, Pelley RJ, Kursh ED, Resnick MI, Bodner DR, Jacobberger JW, Delmoro CM, Giaconia JM. (1993). Xenografts of primary human prostatic carcinoma. J Natl Cancer Inst, 85, 394–398.
   PubMedGoogle Scholar
• Schroeder A, Avnir Y, Weisman S, Najajreh Y, Gabizon A, Talmon Y, Kost J, Barenholz Y. (2007). Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility. Langmuir, 23, 4019–4025.
   PubMed Web of Science ®Google Scholar
• Schroeder A, Honen R, Turjeman K, Gabizon A, Kost J, Barenholz Y. (2009a). Ultrasound triggered release of cisplatin from liposomes in murine tumors. J Control Release, 137, 63–68.
   PubMed Web of Science ®Google Scholar
• Schroeder A, Kost J, Barenholz Y. (2009b). Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes. Chem Phys Lipids, 162, 1–16.
   PubMed Web of Science ®Google Scholar
• Sudimack JJ, Guo W, Tjarks W, Lee RJ. (2002). A novel pH-sensitive liposome formulation containing oleyl alcohol. Biochim Biophys Acta, 1564, 31–37.
   PubMed Web of Science ®Google Scholar
• Sundaram J, Mellein BR, Mitragotri S. (2003). An experimental and theoretical analysis of ultrasound-induced permeabilization of cell membranes. Biophys J, 84, 3087–3101.
   PubMed Web of Science ®Google Scholar
• Woodle MC, Collins LR, Sponsler E, Kossovsky N, Papahadjopoulos D, Martin FJ. (1992). Sterically stabilized liposomes. Reduction in electrophoretic mobility but not electrostatic surface potential. Biophys J, 61, 902–910.
   PubMed Web of Science ®Google Scholar
• Woodle MC, Newman MS, Cohen JA. (1994). Sterically stabilized liposomes: physical and biological properties. J Drug Target, 2, 397–403.
   PubMed Web of Science ®Google Scholar
• Working PK, Dayan AD. (1996). Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). Hum Exp Toxicol, 15, 751–785.
   PubMed Web of Science ®Google Scholar